Table 3.
Responses on the management of the inflammatory arthritis in patient with a 6-week unplanned pregnancy with conventional synthetic disease modifying anti-rheumatic drugs, biologics/small molecules, and other medications
| Continue drug, continue pregnancy (%) | Stop drug, continue pregnancy (%) | Continue drug, counsel regarding termination (%) | Stop drug, counsel regarding termination (%) | Not sure (%) | |
|---|---|---|---|---|---|
| Conventional synthetic disease modifying anti-rheumatic drugs | |||||
| Azathioprine | 80.3* | 6.1 | 1.5 | 4.5 | 7.6 |
| Chloroquine | 71.2 | 7.6 | 3.0 | 0 | 18.2 |
| Cyclophosphamide | 0 | 16.7 | 13.6 | 60.6 | 9.1 |
| Cyclosporine | 27.3 | 18.2 | 1.5 | 19.7 | 33.3 |
| Doxycycline | 0 | 29.2 | 0 | 6.2 | 64.6 |
| Gold salts | 30.3 | 18.2 | 0 | 9.1 | 42.4 |
| Hydroxychloroquine | 90.9* | 4.5 | 1.5 | 0 | 3.0 |
| Leflunomide | 0 | 16.7 | 6.1 | 69.7 | 7.6 |
| Methotrexate | 0 | 22.7 | 7.6 | 65.2 | 4.5 |
| Minocycline | 0 | 34.8 | 0 | 6.1 | 69.7 |
| Mycophenolate mofetil | 3.0 | 19.7 | 10.6 | 47.0 | 19.7 |
| Sulfasalazine | 76.6* | 14.1 | 0 | 1.6 | 7.8 |
| Biologics/small molecules | |||||
| Abatacept | 24.2 | 45.5 | 1.5 | 6.1 | 22.7 |
| Adalimumab | 66.7 | 25.8 | 1.5 | 1.5 | 4.5 |
| Anakinra | 15.2 | 39.4 | 1.5 | 4.5 | 39.4 |
| Apremilast | 4.6 | 35.4 | 0 | 6.2 | 53.8 |
| Certolizumab | 63.1 | 26.2 | 1.5 | 0 | 9.2 |
| Etanercept | 69.7 | 24.2 | 0 | 1.5 | 4.5 |
| Golimumab | 60.6 | 28.8 | 1.5 | 1.5 | 7.6 |
| Infliximab | 60.0 | 29.2 | 1.5 | 1.5 | 7.7 |
| Rituximab | 18.2 | 39.4 | 1.5 | 6.1 | 34.8 |
| Tocilizumab | 18.2 | 39.4 | 1.5 | 4.5 | 36.4 |
| Tofacitinib | 3.0 | 31.8 | 0 | 7.6 | 57.6 |
| Ustekinumab | 13.8 | 33.8 | 1.5 | 4.6 | 46.2 |
| Other medications | |||||
| Celecoxib | 39 | 56 | 0 | 0 | 3 |
| Ibuprofen | 64 | 33 | 0 | 0 | 3 |
| Naproxen | 65 | 32 | 0 | 0 | 3 |
| Prednisone | 85* | 12 | 0 | 0 | 3 |
*Indicates consensus among respondents based on a priori cut-off of ≥75%